Skip to main content
. Author manuscript; available in PMC: 2008 Oct 24.
Published in final edited form as: Oncogene. 2007 Nov 26;27(19):2716–2727. doi: 10.1038/sj.onc.1210934

Figure 4.

Figure 4

Oligonucleotide-mediated siRNA knockdown of E2F3 in bladder tumour-derived cell lines with 6p22 amplification and telomerase-immortalised normal human urothelial cells (NHUC-TERT). (a) Western blot analysis of E2F3 in protein lysates from 6p22-amplified cells (5637 and TCC-SUP) and NHUC-TERT targeted with E2F3a-specific siRNA oligonucleotides. (b) Fold change in adherent cell number of 5637, TCC-SUP and NHUC-TERT cells with targeted knockdown of E2F3a expression. (c) Western blot analysis of E2F3 in protein lysates from 6p22-amplified cells (JMSU-1 and 5637) targeted with E2F3a-, E2F3b- or E2F3a+b-specific siRNA oligonucleotides. (d) Viable (white bars) and total (black bars) cell counts of JMSU-1 and 5637 cells targeted with E2F3 siRNA oligonucleotides. (e) Western blot analysis of CDC2 expression in JMSU-1 cells with targeted knockdown of E2F3.